Skip to main content
SpringerLink
Log in
Book cover

Molecular Genetic Pathology pp 181–196Cite as

Modern Immunohistochemistry in Targeted Therapy

  • Reference work entry
  • First Online:

Abstract

Immunohistochemistry is the application of antibodies with predefined specificities to tissue sections, coupled with the use of highly sensitive detection systems permitting visualization of the antibody target. While traditionally immunohistochemistry has been employed to identify cell type-specific proteins which can reveal the direction of differentiation of tumors, more recently immunohistochemistry has been employed as “companion diagnostics” to identify the presence or absence, or to quantify the amount, of targets of various targeted therapies for cancer. These include the estrogen (and progesterone) receptors in breast cancer, the target of agents such as tamoxifen; the HER2 transmembrane receptor expressed by a subset of breast (and other) cancers, the target of the humanized monoclonal antibody, trastuzumab; the mutated c-kit transmembrane receptor of gastrointestinal stromal tumors, the target of imatinib; and CD20, the molecule expressed by B cells and B cell malignancies, the target of the humanized monoclonal antibody, rituximab. The use and limitations of immunohistochemistry to predict response to these novel reagents is reviewed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   249.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Further Reading

  • Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.

    PubMed  CAS  Google Scholar 

  • Allred D, Carlson R, Berry D, Burstein H, Edge S, Goldstein L, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(Suppl 6):S1–21.

    PubMed  CAS  Google Scholar 

  • Apple S, Pucci R, Lowe A, Shintaku I, Shapourifar-Tehrani S, Moatamed N. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. Am J Clin Pathol. 2011;135:592–8.

    Article  PubMed  Google Scholar 

  • Badve S, Baehner F, Gray R, Childs B, Maddala T, Liu M, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473–81.

    Article  PubMed  Google Scholar 

  • Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane adjuvant multinational trial. J Clin Oncol. 2011;29:1531–8.

    Article  PubMed  CAS  Google Scholar 

  • Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast. 2003;12:92–8.

    Article  PubMed  CAS  Google Scholar 

  • Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004;121:620–30.

    Article  PubMed  Google Scholar 

  • Brock JE, Hornick JL, Richardson AL, Dillon DA, Lester SC. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009;132:396–401.

    Article  PubMed  Google Scholar 

  • Burry RW. Immunocytochemistry: a practical guide for biomedical research. New York: Springer; 2009.

    Google Scholar 

  • Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, et al. HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw. 2006;4(Suppl 3):S1–22.

    Google Scholar 

  • Cheang MCU, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637–44.

    Article  PubMed  CAS  Google Scholar 

  • Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913–9.

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613–26.

    Article  PubMed  CAS  Google Scholar 

  • Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16–20.

    Article  PubMed  Google Scholar 

  • Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–75.

    PubMed  CAS  Google Scholar 

  • Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611–5.

    PubMed  CAS  Google Scholar 

  • Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–6.

    Article  PubMed  CAS  Google Scholar 

  • Fang C, Xu W, Li J-Y. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol. 2010;89:1107–13.

    Article  PubMed  CAS  Google Scholar 

  • Fitzgibbons P, Murphy D, Hammond M, Allred D, Valenstein P. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med. 2010;134:930–5.

    PubMed  CAS  Google Scholar 

  • Forstpointner R, Unterhalt M, Dreyling M, Böck H-P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–8.

    Article  PubMed  CAS  Google Scholar 

  • Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol. 2010;49:3–12.

    Article  PubMed  CAS  Google Scholar 

  • Gavrielides MA, Gallas BD, Lenz P, Badano A, Hewitt SM. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. Arch Pathol Lab Med. 2011;135:233–42.

    PubMed  Google Scholar 

  • Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–37.

    Article  PubMed  CAS  Google Scholar 

  • Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86–92.

    Article  PubMed  Google Scholar 

  • Gown A. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(Suppl 2):S8–15.

    Article  PubMed  CAS  Google Scholar 

  • Gown A, Goldstein L. The knowns and the unknowns in HER2 testing in breast cancer. Am J Clin Pathol. 2011;136:5–6.

    Article  PubMed  CAS  Google Scholar 

  • Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21:1271–7.

    Article  PubMed  CAS  Google Scholar 

  • Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29:105–12.

    Article  PubMed  Google Scholar 

  • Haines 3rd GK, Wiley E, Susnik B, Apple S, Frkovic-Grazio S, Reyes C, et al. HER2 in well differentiated breast cancer: is testing necessary? Breast Cancer Res Treat. 2008;112:551–6.

    Article  PubMed  CAS  Google Scholar 

  • Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.

    Article  PubMed  Google Scholar 

  • Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.

    PubMed  CAS  Google Scholar 

  • Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–703.

    Article  PubMed  CAS  Google Scholar 

  • Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003a;21:4342–9.

    Article  PubMed  CAS  Google Scholar 

  • Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003b;299:708–10.

    Article  PubMed  CAS  Google Scholar 

  • Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.

    Article  PubMed  CAS  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.

    Article  PubMed  CAS  Google Scholar 

  • Hodi Z, Chakrabarti J, Lee AHS, Ronan JE, Elston CW, Cheung KL, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol. 2007;60:299–302.

    Article  PubMed  Google Scholar 

  • Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981a;75:734–8.

    PubMed  CAS  Google Scholar 

  • Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981b;29:577–80.

    Article  PubMed  CAS  Google Scholar 

  • Ibarra JA, Rogers LW. Fixation time does not affect expression of HER2/neu: a pilot study. Am J Clin Pathol. 2010;134:594–6.

    Article  PubMed  Google Scholar 

  • Ibarra J, Rogers L, Kyshtoobayeva A, Bloom K. Fixation time does not affect the expression of estrogen receptor. Am J Clin Pathol. 2010;133:747–55.

    Article  PubMed  Google Scholar 

  • Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121–43.

    Article  PubMed  CAS  Google Scholar 

  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.

    Article  PubMed  CAS  Google Scholar 

  • Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457–67.

    Article  PubMed  CAS  Google Scholar 

  • Khoury T, Kulkarni S, Morrison C, Bshara W, Zakharia Y, Edge S. HER2 testing: how to reach a high concordance rate between immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2011;19:424–30.

    Article  PubMed  CAS  Google Scholar 

  • Köhler A, Lauritzen B, Van Noorden CJ. Signal amplification in immunohistochemistry at the light microscopic level using biotinylated tyramide and nanogold-silver staining. J Histochem Cytochem. 2000;48:933–41.

    Article  PubMed  Google Scholar 

  • Lee AHS, Key HP, Bell JA, Hodi Z, Ellis IO. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology. 2012;60:880–4.

    Article  PubMed  Google Scholar 

  • Lehr H-A, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997;45:1559–65.

    Article  PubMed  CAS  Google Scholar 

  • Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148–54.

    Article  PubMed  Google Scholar 

  • Mayer G, Bendayan M. Biotinyl-tyramide: a novel approach for electron microscopic immunocytochemistry. J Histochem Cytochem. 1997;45:1449–54.

    Article  PubMed  CAS  Google Scholar 

  • Miwa S, Nakajima T, Murai Y, Takano Y, Sugiyama T. Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol. 2008;43:531–7.

    Article  PubMed  CAS  Google Scholar 

  • Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011;136:754–61.

    Article  PubMed  Google Scholar 

  • Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–54.

    Article  PubMed  CAS  Google Scholar 

  • Motta G, Cea M, Moran E, Carbone F, Augusti V, Patrone F, et al. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol. 2010;2010:428253.

    Article  PubMed  Google Scholar 

  • Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs. 1999;58:79–88.

    Article  PubMed  CAS  Google Scholar 

  • Osamura R, Gown A. Personalized medicine-molecular targeted cancer therapy. J Cell Mol Med. 2009;13:4285.

    Article  PubMed  Google Scholar 

  • Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63–72.

    PubMed  CAS  Google Scholar 

  • Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–8.

    Article  PubMed  Google Scholar 

  • Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996;77:2514–9.

    Article  PubMed  CAS  Google Scholar 

  • Polak JM, Van Noorden S. Introduction to Immunocytochemistry. 3rd ed. Oxford: Bios; 2003.

    Google Scholar 

  • Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095–105.

    PubMed  CAS  Google Scholar 

  • Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou J-Y, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598–607.

    Article  PubMed  CAS  Google Scholar 

  • Qiu J, Kulkarni S, Chandrasekhar R, Rees M, Hyde K, Wilding G, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol. 2010;134:813–9.

    Article  PubMed  CAS  Google Scholar 

  • Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7:153–7.

    Article  PubMed  Google Scholar 

  • Renshaw S. Immunohistochemistry. Oxfordshire: Scion; 2007.

    Google Scholar 

  • Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000a;53:688–96.

    Article  PubMed  CAS  Google Scholar 

  • Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000b;53:292–301.

    Article  PubMed  CAS  Google Scholar 

  • Rhodes A, Jasani B, Barnes D, Bobrow L, Miller K. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000c;53:125–30.

    Article  PubMed  CAS  Google Scholar 

  • Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol. 2004;122:51–60.

    Article  PubMed  Google Scholar 

  • Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125–38.

    Article  PubMed  CAS  Google Scholar 

  • Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51:506–11.

    Article  PubMed  CAS  Google Scholar 

  • Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–14.

    Article  PubMed  CAS  Google Scholar 

  • Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741–8.

    Article  PubMed  CAS  Google Scholar 

  • Shi SR, Imam SA, Young L, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem. 1995;43:193–201.

    Article  PubMed  CAS  Google Scholar 

  • Shi SR, Cote RJ, Yang C, Chen C, Xu HJ, Benedict WF, et al. Development of an optimal protocol for antigen retrieval: a “test battery” approach exemplified with reference to the staining of retinoblastoma protein (pRB) in formalin-fixed paraffin sections. J Pathol. 1996;179:347–52.

    Article  PubMed  CAS  Google Scholar 

  • Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem. 1997;45:327–43.

    Article  PubMed  CAS  Google Scholar 

  • Shi SR, Shi Y, Taylor CR. Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem. 2011;59:13–32.

    Article  PubMed  CAS  Google Scholar 

  • Skaland I, Nordhus M, Gudlaugsson E, Klos J, Kjellevold KH, Janssen EAM, et al. Evaluation of 5 different labeled polymer immunohistochemical detection systems. Appl Immunohistochem Mol Morphol. 2010;18:90–6.

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.

    Article  PubMed  CAS  Google Scholar 

  • Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.

    Article  PubMed  CAS  Google Scholar 

  • Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258–67.

    Article  PubMed  CAS  Google Scholar 

  • Taylor CR. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer. 1996;77:2419–22.

    Article  PubMed  CAS  Google Scholar 

  • Taylor CR, Cote RJ. Immunomicroscopy: a diagnostic tool for the surgical pathologist. 3rd ed. Philadelphia: Saunders Elsevier; 2006.

    Google Scholar 

  • Taylor CR, Shi SR, Chen C, Young L, Yang C, Cote RJ. Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem. 1996;71:263–70.

    Article  PubMed  CAS  Google Scholar 

  • Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22:1071–7.

    Article  PubMed  CAS  Google Scholar 

  • Turbin D, Leung S, Cheang M, Kennecke H, Montgomery K, McKinney S, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2007;110:417–26.

    Article  PubMed  Google Scholar 

  • Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–8.

    Article  PubMed  CAS  Google Scholar 

  • Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, et al. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol. 2004;12:8–13.

    Article  PubMed  Google Scholar 

  • van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301.

    Article  PubMed  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.

    Article  PubMed  CAS  Google Scholar 

  • von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M, Georgii A. Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem. 1997;45:1455–9.

    Article  Google Scholar 

  • Vosse BAH, Seelentag W, Bachmann A, Bosman FT, Yan P. Background staining of visualization systems in immunohistochemistry: comparison of the avidin-biotin complex system and the EnVision + system. Appl Immunohistochem Mol Morphol. 2007;15:103–7.

    Article  PubMed  CAS  Google Scholar 

  • Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016–9.

    Article  PubMed  CAS  Google Scholar 

  • West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107–13.

    Article  PubMed  CAS  Google Scholar 

  • Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.

    Article  PubMed  CAS  Google Scholar 

  • Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PhenoPath Laboratories, Seattle, WA, USA

    Allen M. Gown MD (Medical Director and Chief Pathologist, Clinical Professor of Pathology)

  2. Department of Pathology, University of British Columbia, Vancouver, BC, Canada

    Allen M. Gown MD (Medical Director and Chief Pathologist, Clinical Professor of Pathology)

Authors
  1. Allen M. Gown MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, Dept. Pathology, Indiana University, N. University Blvd. 550, Indianapolis, 46202, Indiana, USA

    Liang Cheng

  2. Dept. Pathology, Mount Sinai School of Medicine, Gustave L. Levy Place 1, New York, 10029, New York, USA

    David Y. Zhang

  3. School of Medicine, Department of Pathology and, Indiana University, 635 Barnhill Drive, Indianapolis, 46202, Indiana, USA

    John N. Eble

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this entry

Cite this entry

Gown, A.M. (2013). Modern Immunohistochemistry in Targeted Therapy. In: Cheng, L., Zhang, D., Eble, J. (eds) Molecular Genetic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4800-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4800-6_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4799-3

  • Online ISBN: 978-1-4614-4800-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation